BioXcel Therapeutics Appoints June Bray to Board of Directors
March 01 2021 - 7:00AM
BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq:
BTAI), a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology, today announced the
appointment of June Bray to its Board of Directors. Ms. Bray brings
over forty years of extensive U.S. and global regulatory experience
in the healthcare industry and most recently served as Senior Vice
President, Global Regulatory Affairs and Medical Writing at
Allergan.
“June is a pharmaceutical industry veteran with
a proven track record in leading successful regulatory activities
for both investigational and marketed products in various
therapeutic areas,” commented Vimal Mehta, Chief Executive Officer
of BioXcel. “Her demonstrated achievements, which include 32 New
Drug Approvals (“NDAs”) in the U.S., will provide invaluable
insight as we look to submit our first NDA later this month and
transition to becoming a commercial neuroscience-focused
organization. We are pleased to welcome June to our Board and look
forward to her expertise and guidance as we work toward delivering
transformative medicines to neuropsychiatric patients struggling
with agitation and other stress-related symptoms.”
“I am excited to join BioXcel’s Board as the
Company prepares to transition to a commercial-stage organization,”
said June Bray. “I truly believe BioXcel’s strong neuroscience
program has the potential to change the way patients struggling
with agitation are treated across various settings, ranging from
hospitals to at-home care. Based on my extensive
experience developing strategies for countless global product
approvals, I look forward to working with management and the
members of the Board, sharing my extensive regulatory knowledge to
help BioXcel potentially bring innovative treatments to
patients.”
In her role at Allergan (formerly Actavis/Forest
Research Institute), Ms. Bray was responsible for regulatory
strategies on development projects and lifecycle management in all
therapeutic areas, including psychiatry and neurology, overseeing
more than 400 employees globally. During her tenure, she led
numerous NDA approvals, including Namenda XR®, Namzaric®, Vraylar®,
and Ubrelvy®. Previously, Ms. Bray served as Vice President,
Regulatory Affairs at Organon (now Merck), where she led regulatory
activities for development and marketed products, including the NDA
for Saprhis® (asenapine) for the treatment of schizophrenia and
bipolar disorder. Earlier in her career, Ms. Bray held numerous
roles of increasing responsibility over a 25-year period at Berlex
Laboratories, Inc. (now Bayer HealthCare Pharmaceuticals). She
began her pharmaceutical career in sterile manufacturing at
Hoechst-Roussel Pharmaceuticals (now Sanofi-Aventis). Ms. Bray
holds a B.S. in Pharmacy from the University of Rhode Island and an
M.B.A in Pharmaceutical Marketing from Fairleigh Dickinson
University.
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical-stage
biopharmaceutical company utilizing artificial intelligence
approaches to develop transformative medicines in neuroscience and
immuno-oncology. BioXcel's drug re-innovation approach leverages
existing approved drugs and/or clinically validated product
candidates together with big data and proprietary machine learning
algorithms to identify new therapeutic indices. BioXcel's two most
advanced clinical development programs are BXCL501, an
investigational, proprietary, orally dissolving thin film
formulation of dexmedetomidine for the treatment of agitation and
opioid withdrawal symptoms, and BXCL701, an investigational, orally
administered, systemic innate immunity activator in development for
the treatment of aggressive forms of prostate cancer and advanced
solid tumors that are refractory or treatment naïve to checkpoint
inhibitors. For more information, please visit
www.bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release include but are not limited to the timing of the Company’s
NDA submission, the Company’s intended commercialization plans and
the value of BXCL501 as a potential treatment option. When used
herein, words including "anticipate," "being," "will," "plan,"
"may," "continue," and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance, or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon BioXcel's current expectations and various
assumptions. BioXcel believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
BioXcel may not realize its expectations, and
its beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation, its limited operating history; its incurrence
of significant losses; its need for substantial additional funding
and ability to raise capital when needed; its limited experience in
drug discovery and drug development; its dependence on the success
and commercialization of BXCL501 and BXCL701 and other product
candidates; the failure of preliminary data from its clinical
studies to predict final study results; failure of its early
clinical studies or preclinical studies to predict future clinical
studies; its ability to receive regulatory approval for its product
candidates; its ability to enroll patients in its clinical trials;
undesirable side effects caused by BioXcel's product candidates;
its approach to the discovery and development of product candidates
based on EvolverAI is novel and unproven; its exposure to patent
infringement lawsuits; its ability to comply with the extensive
regulations applicable to it; impacts from the COVID-19 pandemic;
its ability to commercialize its product candidates; and the other
important factors discussed under the caption "Risk Factors" in its
Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2020, as such factors may be updated from time to
time in its other filings with the SEC, accessible on the SEC's
website at www.sec.gov and the Investors section of our website at
www.bioxceltherapeutics.com.
These and other important factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While BioXcel may elect to update
such forward-looking statements at some point in the future, except
as required by law, it disclaims any obligation to do so, even if
subsequent events cause our views to change. These forward-looking
statements should not be relied upon as representing BioXcel's
views as of any date subsequent to the date of this press
release.
Contact Information:
BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com
Investor Relations:
Mary ColemanBioXcel Therapeutics, VP of
Investment
RelationsMColeman@bioxceltherapeutics.com 1.475.238.6837
John GrazianoSolebury
Troutjgraziano@soleburytrout.com 1.646.378.2942
Media:
Julia DeutschSolebury
Troutjdeutsch@soleburytrout.com 1.646.378.2967
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Sep 2023 to Sep 2024